Navigation Links
ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Date:8/5/2010

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015  Michigan brothers Dominique Larkin , 23, and ... ventricular dysplasia, or ARVD, a disease that causes irregular heart ... young athletes. In 2007, doctors discovered the condition ... later tested Dominique and found his "condition was just as ... story in The Ann Arbor News , part of ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of the "Global Ultrasound ... , The Global Ultrasound ... 5.79% over the period 2014-2019 Ultrasound ... sound waves. Ultrasound systems are extensively used by ...
(Date:3/3/2015)... 2015   VWR  (NASDAQ:  VWR), a leading, ... announced today the expansion of its distribution agreement ... allows VWR increased access to NEB,s growing product ... and Puerto Rico.  In addition, customers will now ... platform, sales organization, and VWRCATALYST, our onsite services ...
Breaking Medicine Technology:Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 3Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2VWR Announces Expansion of Distribution Agreement with New England Biolabs 2
... (the "Company") will be a featured guest in an exclusive live interview tonight, ... exclusive interview will be held on Monday, May 14, 2012 at 8:00pm EDT, ... www . investorshub . advfn . ... . Additionally, our show can be heard live directly from our STT Live ...
... 14, 2012  myMatrixx®, a full-service pharmacy benefit management ... announced today that Craig Rollins has joined the ... Development. In this role he will be responsible ... which includes the 1Click Ancillary online marketplace. myMatrixx ...
Cached Medicine Technology:SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio 2SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio 3SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio 4myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development 2
(Date:3/3/2015)... (PRWEB) March 03, 2015 The human ... of the augmentation market. The wearable augmentation sector is ... of size in the upcoming years. , The ... owing to a big number of new products launches ... American region, high technological advancements as well as the ...
(Date:3/3/2015)... it is clear that the prospect of reduced premiums ... signing up to UBI policies, more mature audiences may ... to current regulations, the application of UBI in Canada ... capability is starting to be realised in the US ... are at the top of the value-added services wish-list. ...
(Date:3/3/2015)... 03, 2015 DePuy Pinnacle hip ... version of the artificial hip system caused recipients ... move forward in the federal multidistrict litigation underway ... According to the most recent Master Case List ... 7,350 Pinnacle hip replacement lawsuits are now pending ...
(Date:3/3/2015)... 03, 2015 The number of couples ... to about 15%. This increases to 50% by the ... Cook JL, Yuzpe AA, et al. Estimating the prevalence ... Dr. Jason Hitkari, a reproductive endocrinologist and co-director at ... TCM and clinical director and founder of Acubalance Wellness ...
(Date:3/3/2015)... 2015 The North America ... grow from $1,224.6 million to $1,694.6 million, ... and 2019. , Browse through the TOC ... for an analysis of industry trends and ... and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , An ...
Breaking Medicine News(10 mins):Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2Health News:TU-Automotive: Wawanesa Insurance to Discuss How UBI Can Produce Happy, Loyal Customers 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... AHA Create a Unified National Acute Coronary Syndromes ... DALLAS, May 1 The American College of,Cardiology ... Heart Association,s Get With The Guidelines(SM),(GWTG)-Coronary Artery Disease ... create a national unified registry for measuring and,improving ...
... in Product Sales Driven by Robust Growth in Clinical ... ... record revenue of $44.8 million for the first quarter,of fiscal 2008, an increase ... was $1.9 million, or $(0.03) per share, on a,GAAP basis; first quarter net ...
... seed and oil company will focus on new business development ... ULTRA low linolenic, trans fat-free products., ... an,agreement with two key venture capital firms, securing $4 million ... soybean,products. Asoyia is the innovator and leader in developing and ...
... and elsewhere report what is believed to be the ... of heart tissue and the subsequent damage leading to ... findings from the Multiethnic Study of Atherosclerosis (MESA), to ... Journal of the American College of Cardiology, appear to ...
... HILL, N.C., May 1 Leading pharmaceutical,companies ... recruitment,is part of the critical path in ... Trial Excellence: The Science and Art of ... techniques,that speed clinical trial investigator recruitment and ...
... PHILADELPHIA May 1, 2008 Shire plc ... company, announced today that it will present key ... (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and ... extended release, at the American Psychiatric Association (APA) ...
Cached Medicine News:Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 2Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 3Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:Asoyia Secures Venture Capital Funding 2Health News:Asoyia Secures Venture Capital Funding 3Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Strategies for Winning Clinical Investigators in a Competitive Marketplace 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
Angled 45 degree shafts with 10.5 mm tying platform. 1 mm of tip is crisscross serrated. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 4.0 inches....
Angled shafts with 10 mm tying platform. True round knurled handle in the closed position with polished finish. Overall length 4.2 inches....
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Medicine Products: